4 Reasons Social Security Is In Trouble - Will You Be, Too?
Worst Things to Buy Before Your Kid Heads Back to School
Monkeys' Behavior Reveals Hidden Threat to Our Wealth
Can Apple Restore the Luster of the iPad?
Sabby reports 6.9% passive stake in Athersys
Athersys files to sell 17M shares of common stock
Athersys Wraps Up MultiStem Enrollment
Athersys price target raised to $6 from $3 at Maxim
Athersys (ATHX) Pops Higher on Strong MultiStem Data in Treating MS
Athersys Presents Research Progress in Its Multiple Sclerosis Program
Orbimed lowers stake in Athersys to 3.48% from 5.56%
Athersys reports on progress in Phase 2 study of MultiStem for ischemic stroke
Athersys Reports on Progress in Phase 2 Study of MultiStem for Ischemic Stroke
Can Stem Cells Regenerate Your Portfolio? Stephen Dunn Says Yes